Boxer M, Ellman L, Carvalho A
Arthritis Rheum. 1976 Nov-Dec;19(6):1244-8. doi: 10.1002/art.1780190603.
The clinical and laboratory experience with the lupus anticoagulant was reviewed in 37 patients. The anti-coagulant is thought to act by blocking the activation of prothrombin by the prothrombin activator comlex of factors Xa, V, and phospholipid. Although the anticoagulant has been principally associated with diseases of immune origin, 14 of the present patients had disorders not thought to be immune in nature. Eighteen patients underwent twenty-one operative procedures with only a single episode of excessive bleeding. In the author's experience, the lupus anticoagulant is a rare cause of bleeding.
回顾了37例狼疮抗凝物患者的临床和实验室经验。这种抗凝物被认为是通过阻断由Xa因子、V因子和磷脂组成的凝血酶原激活物复合物对凝血酶原的激活而起作用。尽管这种抗凝物主要与免疫源性疾病相关,但目前的患者中有14例患有非免疫性疾病。18例患者接受了21次手术,仅发生了1次出血过多的情况。根据作者的经验,狼疮抗凝物是一种罕见的出血原因。